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A B S T R A C T
According to the latest Global Burden of Disease Study data, non-communicable diseases in general and car-
diovascular disease (CVD) in particular are the leading cause of premature death and reduced quality of life.
Demographic shifts, unhealthy lifestyles and a higher burden of adverse environmental factors provide an ex-
planation for these findings. The expected growing prevalence of CVD requires enhanced research efforts for
identification and characterisation of novel therapeutic targets and strategies. Cardiovascular risk factors in-
cluding classical (e.g. hypertension, diabetes, hypercholesterolaemia) and non-classical (e.g. environmental
stress) factors induce the development of endothelial dysfunction, which is closely associated with oxidant stress
and vascular inflammation and results in CVD, particularly in older adults. Most classically successful therapies
for CVD display vasoprotective, antioxidant and anti-inflammatory effects, but were originally designed with
other therapeutic aims. So far, only a few ‘redox drugs’ are in clinical use and many antioxidant strategies have
not met expectations. With the present review, we summarise the actual knowledge on CVD pathomechanisms,
with special emphasis on endothelial dysfunction, adverse redox signalling and oxidative stress, highlighting the
preclinical and clinical evidence. In addition, we provide a brief overview of established CVD therapies and their
relation to endothelial dysfunction and oxidative stress. Finally, we discuss novel strategies for redox-based CVD
therapies trying to explain why, despite a clear link between endothelial dysfunction and adverse redox sig-
nalling and oxidative stress, redox- and oxidative stress–based therapies have not yet provided a breakthrough in
the treatment of endothelial dysfunction and CVD.
1. Introduction
1.1. Epidemiological evidence for a leading role of cardiovascular disease in
global burden of disease and premature deaths – central role of endothelial
dysfunction in cardiovascular morbidity
As shown by results of the Global Burden of Disease Study, non-
communicable diseases (NCD) such as atherosclerosis are gaining im-
portance for the global burden of disease and premature deaths,
outcompeting communicable childhood diseases as the leading drivers
for premature death1 and life years spent with severe illness or dis-
ability (DALYs2) [1,2]. This shift is most likely due to an aging popu-
lation with an increased prevalence of NCD and classical risk factors
such as hypertension, unhealthy lifestyle (e.g. smoking, inactivity, un-
healthy diet, work strain) and environmental factors [3], which out-
weigh genetic factors by far [4]. The four primary risk factors and
diseases for global premature deaths in 2010 were hypertension,
ischaemic heart disease, smoking and cerebrovascular disease [2],
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whereas the five primary risk factors in 2015 were hypertension,
smoking, high fasting blood glucose, high total cholesterol and ambient
air pollution (particulate matter 2.5 μm) [5], all related to cardiovas-
cular complications.
Surprisingly, the Global Burden of Disease Study estimates that all
forms of pollution were responsible for as many as 268 million DALYs
[6], with air pollution a leading trigger of premature deaths [7,8]. This
number is considerable, given that around 422 million people were
affected by diabetes [9] in 2014 and 1.6 million global deaths were
directly caused by diabetes, with another 2.2 million deaths attribu-
table to high blood glucose – a well-accepted primary risk factor. In
fact, diabetes mellitus is an accepted independent risk factor in the
development of coronary heart disease with a notable adverse effect on
survival; in diabetics, the risk of death from coronary artery disease is
two-to four-fold higher [10], according to a meta-analysis reporting a
hazard ratio for cardiovascular mortality in screening-detected diabetes
of 3.42 (95% confidence interval [CI]: 2.23–5.23) [11]. Additionally,
the risk of myocardial infarction (MI) for diabetics diagnosed within 10
years without a preceding MI is equal to the risk level of non-diabetics
with a previous MI [10].
All known risk factors of atherosclerosis lead to the development of
endothelial dysfunction, which precedes the progression of athero-
sclerotic plaques and represents an early (subclinical) correlate of
atherosclerosis [12,13] (reviewed in [14]). Indeed, as evidenced by
multiple experimental and clinical studies, various classical risk factors
(e.g. hypercholesterolaemia [12], hypertension [13,15], chronic
smoking [16], diabetes mellitus [17]) or non-classical risk factors, such
as novel environmental risk factors (e.g. traffic noise exposure [18,19],
ambient air pollution [20,21] and mental stress [22,23]) or chronic
inflammatory disease (e.g. rheumatoid arthritis [24,25], psoriasis [26])
each induce endothelial dysfunction. Endothelial dysfunction is also
correlated with markers of chronic (low-grade) inflammation such as C-
reactive protein (CRP) [27] and cardiovascular risk predictors such as
adiponectin and brain natriuretic peptide (BNP) [28,29]. Moreover, the
presence of several risk factors produces additive (or sometimes even
synergistic) effects on endothelial function as well as the associated
cardiovascular prognosis [30]. Previous studies have confirmed that
hypercholesterolaemia or chronic smoking led to moderate impairment
of endothelial function (reduction of the maximal acetylcholine-de-
pendent vasodilation by ~30%), whereas the presence of both risk
factors caused severe (additive) endothelial dysfunction (reduction of
the maximal acetylcholine-dependent vasodilation by ~60%) [31].
Thus, all risk factors identified so far seem to collectively impair the
vasoprotective mechanisms of endothelium, including impairment of
nitric oxide (NO)-dependent function promoting oxidative stress, and
pro-thrombotic and pro-inflammatory maladaptive mechanisms leading
to the development of endothelial dysfunction, atherosclerotic plaques
and clinical consequences such as MI, ischaemic stroke and peripheral
artery diseases [32–38] (Fig. 1).
Impaired endothelium-dependent vasodilation has prognostic im-
plications, as it predicts adverse cardiovascular events and poor long-
term outcomes in patients with risk factors [38–40] or in healthy in-
dividuals [33,41]. Accordingly, endothelial dysfunction may be re-
garded as a barometer of cardiovascular risk [38], representing an in-
tegrated index of all atherogenic and atheroprotective factors present in
an individual. This may be useful to stratify cardiovascular risk and
identify individuals at higher risk [32,35,42–44], having greater pre-
dictive value than traditional risk factors [35,41,45] in patients treated
optimally according to the medical standards of today [46,47]. Thus,
endothelial dysfunction has not only pathophysiological and diagnostic
but also important therapeutic significance in atherosclerosis and car-
diovascular diseases (CVD).
1.2. Endothelial dysfunction is associated with oxidative stress and vascular
inflammation
Endothelial dysfunction is closely interconnected with oxidative
stress as well as with vascular inflammation, representing unifying
Fig. 1. Cardiovascular risk factors and manifestations of cardiovascular disease. Risk factors collectively impair NO-dependent signalling and induce en-
dothelial dysfunction, with a central role for the loss of homeostatic •NO/O2•‾ balance, induction of oxidative stress and low-grade inflammation.
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concepts for the underlying pathophysiology of cardiovascular mor-
bidity and mortality [48,49]. Indeed, low-grade inflammation is a
contributor to the hallmark oxidative stress associated with most CVD
[50–52], and thus represents a cardiovascular risk factor [53] that can
be targeted by pharmacological treatment [54]. Accordingly, psoriasis
has been classified as an independent risk factor for CVD [26] and the
European League against Rheumatism recommends cardiovascular
therapy for patients with psoriasis [55]. Similarly, rheumatoid arthritis
is an important contributor to cardiovascular morbidity [56]. Either
psoriasis or rheumatoid arthritis–associated inflammation may result in
endothelial dysfunction [57,58]. In line with this, the systolic blood
pressure of patients with rheumatoid arthritis or psoriasis is reduced by
immune-suppressive therapy [59]. Furthermore, inflammation is an
important player in various chronic diseases including chronic kidney
disease, non-alcoholic fatty liver disease (NAFLD) and neurodegenera-
tion, which are all either triggered by or associated with low-grade
inflammation [60–62] and associated with endothelial dysfunction
[63–65]. Thus, chronic inflammatory diseases are interrelated with
CVD and have a common denominator – inflammation. The accumu-
lated evidence on the major role of inflammation in CVD has led to
clinical trials of IL-1 receptor blockers or antagonists (Anakinra, rilo-
nacept, canakinumab [CANTOS trial], gevokizumab) in patients with
CVD that are underway or already completed [66], with encouraging
results for further studies.
Of note, low-grade inflammation is a hallmark of the aging process
(immunosenescence) [49,67] and contributes to a higher prevalence of
metabolic and cardiovascular complications in older adults [68], with
vascular aging exemplifying the close interrelationship of low-grade
inflammation with endothelial dysfunction and oxidant stress.
The concept of “vascular aging” refers today to all age-associated
changes in vessels, leading to an increased prevalence of atherosclerotic
lesions, vascular injury, impaired angiogenesis, calcification and stiff-
ness [69], and endothelial as well as smooth muscle cells contribute to
these phenomena [70]. Importantly, impaired endothelium-dependent
relaxation (endothelial dysfunction) in older adults is also linked to
impaired vascular regulation [71,72]. Age-dependent endothelial dys-
function is found in all vessels, from macrovessels such as the aorta and
coronary arteries to resistance vessels of the microcirculatory system
(for review see Ref. [73]), which is mirrored by other disorders related
to aging vessels, such as erectile dysfunction, renal dysfunction, Alz-
heimer's disease and retinopathy [74–77]. Impaired nitric oxide radical
(•NO) signalling, vascular inflammation and oxidative stress are key
players in the pathogenesis of age-dependent endothelial dysfunction
[78], as demonstrated by our groups and many others [79] (for review
see Ref. [67,80]). In combination, these data all implicate aging as an
independent risk factor for CVD, mainly due to oxidative stress–induced
endothelial dysfunction and low-grade inflammation [81,82].
Similarly, in a population-based study (n = 631), type 2 diabetes
mellitus (T2DM) was cross-sectionally associated with both endothelial
dysfunction and low-grade inflammation, explaining approximately
43% of the increase in cardiovascular mortality risk in the diabetic
group [83]. Likewise, markers of inflammation (CRP, IL-6 and TNF-α),
show a positive correlation with increasing HbA1c values [84], and
increased markers of inflammation are associated with a higher risk of
T2DM development [85]. Cardiovascular complications in diabetes
mellitus are associated with oxidative stress [86,87], as are hypercho-
lesterolaemia and arteriosclerosis [88,89].
Therefore, it seems that there is a close interaction (crosstalk) be-
tween inflammatory pathways, oxidative stress and endothelial dys-
function [50]. Better understanding the relationship between these
three major hallmarks of vascular pathology and CVD is an important
challenge. For example, mitochondrial oxidative stress (mtROS) for-
mation increases with advancing age [67,80] and leads to the activation
of immune cells and their phagocytic NADPH oxidase, thereby stimu-
lating cytokine release and the inflammasome [90–95]. Therefore,
normalising the chronic inflammatory phenotype and additionally
targeting mtROS could represent a promising strategy to increase
healthspan [96].
1.3. Endothelial dysfunction in other diseases – endothelial biomedicine
Apart from atherosclerosis, multiple other diseases have been
identified in which endothelial dysfunction has a pathophysiological
role. Endothelial dysfunction plays a key role in cancer metastasis, as it
is present both locally in metastatic organs and in systemic vasculature,
and may promote activation of platelets as well as pro-thrombotic and
pro-inflammatory mechanisms [97,98]. Endothelial dysfunction also
has a pathophysiological role in pulmonary hypertension [99], non-
ischaemic heart failure [100], sepsis [101,102], preeclampsia [103],
malaria [104], dengue viral infections [105], Chagas disease [106],
trauma [107] and many other diseases that cannot be listed and re-
ferenced here due to limited space.
Altogether, more than 300,000 published articles relate to en-
dothelium, and endothelial biomedicine – the discipline with the term
coined by William C Aird – is expanding progressively [108]. However,
despite the increasingly recognised role of endothelium-related me-
chanisms in cardiovascular and non-cardiovascular disease, the
knowledge in endothelial biomedicine that has accumulated over the
years has not yet been translated into endothelium-guided diagnostics
and endothelium-targeted disease therapies. There are a number of
possible reasons for this [109]. However, one of the major limitations to
fostering pharmacology of endothelium is the fact that the methods
available to diagnose endothelial function in clinical settings are not
suited for everyday clinical practice. We briefly summarise this issue in
Section 1.4. However, the major aim of this review is to explain why -
despite the fact that endothelial dysfunction is mechanistically linked
with alterations in redox signalling and oxidative stress - redox and
oxidative stress–based therapies have not yet provided a breakthrough
in the treatment of endothelial dysfunction and CVD.
1.4. Endothelial function measurements in humans
In clinical conditions, a dysfunctional endothelium is diagnosed
based on the impairment of NO-dependent vasodilation initially with
the use of angiography [110] or venous occlusion plethysmography
[111], nowadays mostly by Doppler ultrasonography in a conduit ar-
tery, and by arterial tonometry and finger plethysmography in per-
ipheral circulation [112,113]. Flow-mediated dilation (FMD) by Dop-
pler ultrasonography represents a gold standard approach to assess
endothelial function in humans [114], being the method of reference,
though it has a number of limitations [115]. Recently, a novel magnetic
resonance imaging (MRI)-based approach to assess FMD was proposed
for detecting artery dilation, which gave concordant results with stan-
dard ultrasound technique in healthy volunteers [116]. MRI also allows
the detection of endothelial permeability in patients [117]. Thus, MRI
technology, with its versatility and accuracy, provides an excellent tool
to gain better insight into the endothelium-dependent mechanisms of
health and disease and should be increasingly used in clinical and pre-
clinical studies [118–123]. However, its use for endothelial function
testing is still limited.
Recently, an interesting non-invasive approach to measure micro-
vascular endothelial function was introduced – flicker-induced retinal
dilatation (dynamic retinal vessel analysis [DVA]), which is considered
an NO-dependent response and thus represents a novel approach to
study endothelial NO-dependent function in microvasculature [124].
Impairment of retinal vessel dilation in response to flicker light sti-
mulation was a strong independent predictor of all-cause mortality in
patients with end-stage kidney disease [125] and was also impaired in
prediabetes and diabetes mellitus [126,127], hypertension [128] and
stable coronary artery disease (CAD), particularly in patients with im-
paired left ventricular function [129].
Even though consensus exists that endothelial dysfunction can be
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evaluated in macrocirculation and microcirculation, and a number of
classical techniques (e.g. FMD, reactive hyperaemia–peripheral arterial
tonometry) and novel approaches (e.g. MRI-based measurements of
FMD, endothelial permeability, DVA) are available to measure en-
dothelial function in humans, how to use them routinely in clinical
settings is yet undetermined. The predictive value of gold-standard
FMD is still disputed by some authors. A meta-analysis of 15 cohort
studies supported a predictive value of endothelial function measure-
ments using FMD in patients with diagnosed atherosclerosis [130], and
a number of studies have highlighted the value of FMD in
predicting risk in patients with cardiovascular risks factors
[33,38,40,42,43,45,112,115]. Results of the general population–based
Gutenberg Health Study (5,000 individuals) revealed a strong correla-
tion between the biomarker of CVD, pro-atrial natriuretic peptide
(ANP), and non-invasive measurement of conduit artery and peripheral
arterial performance [131]. These reports are contrasted by the failure
of endothelial function to predict cardiovascular events in mostly
healthy individuals [132] and in those with intermediate cardiovas-
cular risk [133]. According to another large population-based study,
non-invasive measurement of vascular function failed to add prognostic
value to the European Society of Cardiology risk score [134]. Therefore,
measurements of intima–media thickness [132] and stiffness index
[135] were recommended for more accurate determination of en-
dothelial and vascular function, especially since intima–media thick-
ness also correlates with redox state and early atherosclerosis [136].
The authors of this present review share the opinion that the above
controversies, limitations of some of the techniques used to assess en-
dothelial function in humans, and limited use of endothelial tests in
clinical practice are the major obstacles to fostering endothelium-
guided diagnostics and endothelium-targeted disease therapies to
clinical reality and represent the major determinant of the huge bench-
to-bedside gap in endothelial biomedicine [109]. Despite these limita-
tions in the methodologies to reliably assess endothelial function in
humans, it is clear that endothelial dysfunction in conduit vessels is
mechanistically linked with oxidative stress, as it was demonstrated
that vitamin C improved NO-dependent function and the magnitude of
this effect had a prognostic value [89]. This underscores oxidant stress
as an important hallmark of endothelial dysfunction in humans, as
discussed more extensively in Section 2.3.
2. Oxidative stress as a unifying pathomechanism underlying
endothelial dysfunction and cardiovascular disease
2.1. Essential background on the oxidative stress and redox signalling
concept
All aerobic life requires oxygen. Since oxygen is per se a reactive
species, one consequence is that oxygen can be converted to more re-
active molecules (e.g. free radicals) that may cause damage to different
biological molecules and, in the worst case, cause impairment of cel-
lular function [137]. Most CVD is accompanied by an imbalance be-
tween the formation of reactive oxygen and nitrogen species (RONS,
including superoxide, hydrogen peroxide and hydroxyl radicals, and
•NO, as well as products such as peroxynitrite and hypochlorous acid)
and detoxification by low molecular weight antioxidants or reactive
oxygen species (ROS)-degrading enzymes [88,138], leading to a de-
viation from the steady state [139]. Some of these species have a role as
cellular messengers and contribute to redox signalling via S-nitros(yl)
ation, reversible thiol oxidations and ferrous/ferric enzyme equilibria
[140–142]. Among these, the best understood is •NO, which acts as an
important vasodilator and inhibitor of platelet activation [143,144].
The superoxide anion (O2ˉ•) can be formed from different sources such
as xanthine oxidase, NADPH oxidases, uncoupled nitric oxide synthases
(NOS) and the mitochondrial respiratory chain [145]. Of note, •NO can
be antagonised by O2ˉ• radicals leading to the formation of the cytotoxic
oxidant peroxynitrite, as shown by Gryglewski et al. [146]. The
discovery of superoxide dismutases (mitochondrial MnSOD and cyto-
solic/extracellular Cu,Zn-SOD) by Fridovich et al. in the 1960s [147]
provided molecular proof that superoxide plays a role in organisms and
in living cells. Moreover, the existence of enzymes specifically com-
mitted to the scavenging of superoxide, the SODs, implied that in-
appropriately high concentrations of this species may have adverse
effects that contribute to pathological processes.
2.2. Molecular proof for the oxidative stress and redox signalling concept in
animals
The first reports on the role of oxidative stress in the progression
and pathophysiology of CVD were published in the early 1990s by
Harrison and Ohara in an experimental model of hypercholesterolaemia
[148,149]. The molecular proof suggesting the pathophysiological role
of oxidative stress was provided by a large number of preclinical studies
using genetic tools (e.g. knockout mice) which clarified the involve-
ment of ROS-producing or -degrading enzymes in the onset and pro-
gression of these diseases. In mice with MI, genetic deletion of the
NADPH oxidase subunit p47phox almost normalised vascular •NO bioa-
vailability, reduced ROS formation, improved heart function and in-
creased survival rate by 20% after MI [150]. Moreover, deletion of the
NADPH oxidase subunits p47phox and Nox1 had a protective effect on
blood pressure and endothelial function in angiotensin-II (AT–II)–in-
duced hypertension in mice [151,152]. In contrast, overexpression of
Nox1 in these transgenic mice caused a further increase in blood
pressure [153]. Vice versa, partial deletion of the mitochondrial su-
peroxide dismutase (MnSOD+/-) increased age-dependent mitochon-
drial oxidative stress and endothelial dysfunction [154] and rendered
mice more susceptible to nitroglycerin-induced nitrate tolerance and
endothelial dysfunction [155]. Likewise, deletion of the glutathione
peroxidase-1 resulted in increased atherosclerotic plaque lesion size
and vascular oxidative stress in ApoE−/- mice [156].
On the other hand, increasing literature suggests a beneficial role of
ROS in the cardiovascular system, with NOX-4 the major enzymatic
source for protective ROS [157–161], with the exception of ischaemic
stroke, where pharmacological NOX-4 inhibition or deletion of the gene
conferred improved prognosis [162–164]. The NOX-4 paradigm also
represents an attractive explanation for the failure of most large-scale
clinical trials on antioxidants (see Section 2.3), as ROS (mainly H2O2)
also confer beneficial signalling in essential cellular functions, pro-
viding the ‘eustress’ required for maintaining antioxidant defence. An-
tioxidant approaches may require fine-tuned, species-specific, space-
and time-resolved pharmacological targeting (for review see Ref.
[137,165–167]) and, most importantly, complete understanding of
their mode of action [168].
The number of studies on the molecular mechanism of oxidative
stress in animal disease models using genetically modified mice is too
large to be discussed in detail here, but the most important ones, along
with the landmark discoveries on ROS playing a role for CVD are listed
in Table 1. Regarding the numerous animal experimental studies on
pharmacological antioxidant interventions, we would like to refer to
relevant previous review articles [49,60,88,169].
2.3. Molecular proof for the oxidative stress and redox signalling concept in
humans
The close connection between oxidative stress and cardiovascular
prognosis is supported by a number of small-cohort clinical studies (e.g.
by differential effects of vitamin C infusion on FMD in patients with
high or low burden of ROS formation [89]). Examples include the
significantly impaired FMD and reduced circulating glutathione in 52
smokers versus controls [170], a positive correlation between FMD and
superoxide dismutase activity and negative correlations between FMD
and oxLDL/ADMA levels in 59 patients with chronic kidney disease
versus controls [63], and negative correlations between vascular
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function (reactive hyperaemia index) and malondialdehyde/8-oxo-
deoxyguanosine levels in 69 patients with sleep apnoea versus controls
[171]. Large clinical trials have also supported the role of oxidative
stress in cardiovascular prognosis. For example, the levels of glu-
tathione peroxidase-1 showed a positive correlation with cardiovas-
cular event–free survival in 636 individuals [172], and the oxidative
stress serum markers D-ROM (derivatives of reactive oxygen metabo-
lites, indicating ROS levels) and TTL (total thiol levels, representing the
redox state) were independently and strongly associated with all-cause
and CVD mortality in 10,622 men [173]. More large-scale clinical trials
and meta-analyses on the association of oxidative stress markers with
CVD or all-cause mortality are shown in Table 2. Different oxidative
stress markers such as lipid peroxidation products, 3-nitrotyrosine,
oxidative DNA lesions and protein carbonyls were also reviewed in
detail regarding their diagnostic value or association with various dis-
ease (including CVD and a reliability score), reporting the highest level
of evidence for lipid peroxidation products, protein carbonyls, oxidative
DNA lesions, GSH/peroxiredoxin redox state, P-VASP and ADMA, fol-
lowed by 3-nitrotyrosine, 3-chlorotyrosine and MPO [174].
Despite the preclinical and clinical evidence for an important role of
oxidative stress in the development and progression of CVD, there are
to date only a few examples of clinical studies demonstrating that tar-
geted antioxidant drugs (e.g. xanthine oxidase inhibitors, meta-analysis
in 10,684 individuals) [175], α-lipoic acid therapy [176] or tight
control of vitamin C plasma levels (e.g. EPIC-Norfolk trial, 19,496 in-
dividuals [177]) improve the prognosis of patients with CVD. Anti-
oxidant therapy is also beneficial in diseases with proven oxidative
stress conditions such as sickle cell anaemia or thalassaemia, where iron
chelators, α-lipoic acid, N-acetyl cysteine, vitamin E or C, or tetra-
hydrobiopterin therapies are used for prevention of inflammation and
oxidative damage of organs including the cardiovascular system
[178,179]. However, most large clinical trials and meta-analyses (e.g.
HOPE, HOPE-TOO [180]) failed to show any health benefit for the
treatment of CVD or for all-cause mortality with non-selective oral
antioxidant drugs (reviewed in Ref. [165,181]). The synthetic anti-
oxidant drug NXY-059, despite costly development and clinical testing,
also failed to demonstrate any benefit in 3,195 stroke patients [182]. Of
note, these findings are contrasted by a large number of small to in-
termediate-sized clinical interventional trials using either acute vitamin
C infusion with significant cardiovascular health benefits or oral
treatment of individuals at higher risk with improvement of endothelial
dysfunction, a surrogate parameter of early atherosclerosis [14,165].
Some important studies on interventions with classical (oral) anti-
oxidants and dietary interventions, reporting positive and negative
outcomes, are shown in Table 3.
2.4. Molecular mechanism of redox regulation of endothelial function and
redox signalling concept
According to the concept of ‘kindling radicals’ or the ‘bonfire’ hy-
pothesis, the initial formation of superoxide (e.g. from phagocytic
NADPH oxidases of infiltrated leukocytes) and subsequent formation of
peroxynitrite represent the mechanism of eNOS uncoupling [183]. This
kind of ROS-induced ROS formation is also well-known for cross-acti-
vation of mitochondrial ROS formation by dysfunctional mitochondria
[184] or activation of xanthine oxidase and NADPH oxidases
[145,185]. The ROS formation may affect the classical regulatory me-
chanisms of eNOS activity such as calcium and calmodulin, caveolin,
HSP90, palmitoylation and myristoylation that also control the acti-
vating phosphorylation by Akt or AMPK at Ser1179 as well as the lo-
calisation of eNOS. However, ROS formation more directly affects the
non-classical regulation of eNOS activity by so-called ‘redox switches’,
which all may represent pharmacological targets for cardiovascular
therapy: the oxidative depletion of tetrahydrobiopterin (BH4), oxidative
disruption of the dimeric eNOS complex by oxidation of the zinc-sul-
phur-complex, S-glutathionylation of a cysteine in the reductase do-
main and adverse phosphorylation at Thr495/Tyr657, as well as ROS-
triggered increases in levels of the endogenous eNOS inhibitor asym-
metric dimethylarginine (ADMA) or direct oxidative break-down of •NO
itself (for detailed review see Refs. [14,145,183,186]). The functional
correlate of eNOS dysfunction or uncoupling is endothelial dysfunction
in coronary and peripheral vessels, which can be measured by
Table 1
Important (causal) ROS sources or important antioxidant defence enzymes in different animal disease models.
Model and ROS source Reference
Heparin-binding superoxide dismutase significantly lowered arterial blood pressure in spontaneously hypertensive rats [330]
Critical role of the NADPH oxidase subunit p47phox for DOCA-salt-induced hypertension [331]
Critical role of the NADPH oxidase subunit p47phox for AT–II–induced hypertension [151]
Critical role of the NADPH oxidase isoform Nox1 for AT–II–induced hypertension [152,153]
Critical role of mitochondrial ROS for AT–II–induced hypertension [332,333]
Critical role of xanthine oxidase for AT–II–induced hypertension [334]
Critical role of the NADPH oxidase isoform Nox2 (gp91phox) for AT–II–induced hypertension [335–338]
Critical role of the NADPH oxidase isoform Nox4 for AT–II–induced hypertension [339,340]
Critical role of heme oxygenase-1 in cardiovascular protection in hypertension, aging and diabetes models [341,342]
Critical role of the NADPH oxidase subunit p47phox for MI damage [150]
Critical role of the NADPH oxidase isoform Nox4 for MI damage [343]
Critical role of the NADPH oxidase isoform Nox2 for MI damage [344,345]
Critical role of mitochondrial ROS for MI damage [345–347]
Critical role of xanthine oxidase for MI damage [150,348–350]
Crosstalk between mitochondrial and NADPH oxidase–derived ROS in nitroglycerin-triggered vascular dysfunction [351]
Critical role of manganese superoxide dismutase to maintain endothelial function in aged mice and to prevent nitroglycerin-induced oxidative stress [154,155]
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes [352]
Crosstalk of mitochondria and NADPH oxidases via ROS signalling in white blood cells and its relevance in the aging process, AT–II–induced hypertension –
aggravation by MnSOD deficiency and amelioration by cyclophilin D deficiency
[94]
Interaction of mtROS with Nox2 but not Nox1, Nox4 or Nox5 in the AT–II–induced hypertension model via hydrogen peroxide, sSrc, PKCε and mtKATP channels [353]
Mitochondrial regulation of NADPH oxidase in hindlimb unweighting rat cerebral arteries [354]
Genetic endothelial-specific GCH-1 deficiency (Gch1fl/flTie2cre mice) causes eNOS uncoupling and endothelial dysfunction in arterial resistance arteries [355,356]
Genetic endothelial- or myelomonocytic-specific AMPK deficiency (AMPKfl/flTekcre or LysMcre mice) causes endothelial dysfunction, vascular oxidative stress
and inflammation in AT-II induced hypertension
[357,358]
Critical role of the NADPH oxidase isoform Nox2 (gp91phox) for aircraft noise–induced hypertension, endothelial dysfunction, vascular and cerebral oxidative
stress, and inflammation
[359]
Homozygous deletion of SOD2 results in pre- and postnatal death due to dilated cardiomyopathy and neurodegeneration [360,361]
Age-dependent progressive phenotype of low-grade inflammation, vascular oxidative stress and endothelial dysfunction in glutathione peroxidase-1 (GPx-1)
deficient mice
[67,362]
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acetylcholine-dependent (plethysmography) or flow-mediated dilation
and represents an early predictor of cardiovascular events via its direct
connection to the process of atherosclerosis [40,89].
Also down-stream of eNOS, the NO/cGMP signalling pathway con-
tains a number of redox switches. Soluble guanylyl cyclase (sGC) can be
inactivated via thiol oxidation, S-nitrosation [187,188] or ROS-trig-
gered loss of the heme group (reviewed in Ref. [14,189]). Likewise,
cGMP-degrading phosphodiesterases are activated by ROS [190,191].
In contrast, the cGMP-dependent kinase (PKG) is activated by dis-
ulphide bridge protein-dimer formation [192], which could represent a
master switch of a terminal target of the NO/cGMP signalling cascade
to prevent complete loss of this vasodilation pathway.
2.5. Complex phenotype of endothelial dysfunction
The phenotype of endothelial dysfunction is not limited to the loss
of homeostatic •NO/O2•‾ balance and induction of oxidative stress
(Fig. 1) but involves multiple other pathophysiologically relevant al-
terations, including dysregulation of numerous other vasodilator and
vasoconstrictor mediators, diminished glycocalyx coverage and length,
increased endothelial permeability, endothelial (vascular) stiffness,
endothelial inflammation, endothelial pro-thrombotic response and
impaired fibrinolysis (summarised in Fig. 2 along with potential redox
switches in these processes as detailed in Table 4). Other processes
related to smooth muscle and vascular dysfunction such as vascular
stiffness and calcification are discussed elsewhere in detail [193–195].
An important aspect of the complexity of the phenotype of en-
dothelial function is that at least in the murine model of atherosclerosis
relevant to human pathophysiology, multiple endothelial mechanisms
are altered simultaneously in early atherosclerosis even before the oc-
currence of atherosclerotic plaques, as we have demonstrated recently
[122]. In fact, impairment of endothelium-dependent vasodilation and
NO-dependent function, coinciding with glycocalyx injury, increased
endothelial permeability, endothelial stiffness, endothelial inflamma-
tion and changes in haemostasis were all detected in the very early
stage of endothelial dysfunction prior to the development of athero-
sclerotic plaques [122]. These results seem to support the concept of
‘vicious circle’ mechanisms of endothelial dysfunction put recently in
the context of impaired endothelial glycocalyx, endothelial mechan-
otransduction and NO-dependent functions [196]. Numerous studies
support that notion. For example, silencing of glypican-1 or SDC-1 in-
hibited shear stress–induced activation of endothelial NO synthase
[197], while replenishment of the glycocalyx improved mechan-
osensitive NO generation [196]. Increased endothelial cortical stiffness
impaired flow-mediated NO production, suggesting that in pathophy-
siological settings of endothelial dysfunction, NO production is regu-
lated by cortical stiffness, and endothelial nanomechanics appears an
important therapeutic target [198] tightly linked with glycocalyx in-
tegrity [122]. Glycocalyx injury led to increased endothelial perme-
ability [199] and induced a proinflammatory endothelial response
[200], facilitating monocyte adhesion and infiltration, and the devel-
opment of atherosclerotic plaques [201]. Leukocyte infiltration and
Table 2
Important clinical trials or meta-analysis on the association of oxidative stress markers with cardiovascular disease or all-cause mortality. Also reports on effects of CV
drug therapy on oxidative stress markers are listed.
Studies on oxidative stress markers and health effects Marker and outcome Included subjects Reference
Systematic review and meta-analysis on association of 8-hydroxy-2-deoxyguanosine
levels with heart failure
8-OHdG ↑ indicates higher risk 140 Ctr, 446 HF patients [363]
Systematic review and meta-analysis on association of 8-hydroxy-2-deoxyguanosine
levels with CVD
8-OHdG ↑ indicates higher risk 1,106 Ctr, 810 CVD
patients
[364]
Meta-analysis by CHANCES consortium on association of oxidative stress serum
markers with all-cause and CVD mortality
D-ROM ↑ and TTL ↓ indicates higher risk 10,622 (men and women,
age 45–85)
[173]
Meta-analysis on association of circulating oxidised LDL with atherosclerotic
cardiovascular disease
oxLDL ↑ indicates higher risk 12,143 subjects, 2,365 CV
events
[365]
Clinical trial on association of free (F2)-isoprostane with 30-day cardiovascular
outcomes in patients with acute coronary syndrome
8-isoPF2α ↑ indicates higher risk 108 CVD patients, 26
events
[366]
Matched case-control study on association of urinary 8-iso-prostaglandin F2alpha
with cardiometabolic risk factors in patients with coronary heart disease
8-isoPF2α ↑ indicates higher risk 93 Ctr, 93 CHD patients [367]
Clinical trial on association of oxidative stress markers with major adverse
cardiovascular events in patients with coronary artery disease
D-ROM ↑ and OXY-Adsorbent Test indicates
higher risk
97 CAD patients [368]
Clinical trial on association of 8-isoprostane levels with the presence and extent of
coronary stenosis in patients with coronary artery disease
8-isoPF2α ↑ indicates higher risk 241 CAD patients [369]
Clinical trial on association of 3-nitrotyrosine with the presence of coronary artery
disease in patients with prediabetes
3-NT ↑ indicates higher risk 120 prediabetic patients [370]
Clinical trial on association of serum myeloperoxidase levels with endothelial
dysfunction or major adverse cardiovascular events in humans
MPO ↑ indicates higher risk 298 subjects; 3,635
subjects
[371,372]
Clinical trial on association of serum myeloperoxidase levels with CV event risk in
patients with acute coronary syndromes or chest pain
MPO ↑ indicates higher risk 1,090 ACS patients; 490
with chest pain
[373,374]
Clinical trial on association of serum 3-chlorotyrosine levels with acute myocardial
infarction in patients
3-Cl-Tyr ↑ indicates higher risk 53 Ctr, 77 AMI patients [375]
Studies on cardiovascular drug therapy and oxidative stress markers Marker/intervention, outcome Included subjects Reference
Clinical trial on effects of simvastatin therapy on F2-isoprostane formation in
hypercholesterolemic subjects
Statin decreases 8-isoPF2α in
hypercholesterolaemia
43 patients [376]
Clinical trial on effects of simvastatin on endothelial activation and lipid peroxidation
in hypercholesterolaemia
Statin decreases 8-isoPF2α and VCAM-1/E-
Sel in hyperchol.
67 hyperchol. patients, 32
normochol.
[377]
Clinical trial on association of nitrotyrosine levels with cardiovascular disease and
modulation by atorvastatin therapy
Statin decreases 3-NT in CAD 100 non-CAD patients, 100
CAD patients
[378]
Clinical trial on effects of candesartan on endothelial activation and lipid peroxidation
in hypercholesterolaemia
ARB decreases 8-isoPF2α and ICAM-1/MCP-
1 in hyperchol.
47 hyperchol. patients [379]
Abbreviations used are: Ctr (=control); D-ROM (=derivatives of reactive oxygen metabolites, indicating ROS levels) and TTL (=total thiol levels, representing the
redox state); 8-OHdG (=8-hydroxy-2-deoxyguanosine); HF (=heart failure); CVD (=cardiovascular disease); 8-isoPF2α (=8-iso-prostaglandin F2α); CHD (=cor-
onary heart disease); CAD (=coronary artery disease); 3-NT (=3-nitrotyrosine); MPO (=myeloperoxidase); ACS (=acute coronary syndrome); 3-Cl-Tyr (=3-
chlorotyrosine); AMI (=acute myocardial infarction); VCAM-1 (=vascular cell adhesion molecule-1); E-Sel (=E-selectin); ARB (=AT1-receptor blocker); ICAM-1
(=intercellular adhesion molecule-1); MCP-1 (=monocyte chemoattractant protein-1).
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subsequent vascular inflammation further promoted glycocalyx de-
gradation by extrinsic pathways [202]. Inhibition of hyaluronan
synthesis, the major component of the glycocalyx, increased leukocyte
adhesion, endothelial inflammation and progression of atherosclerosis
[203]. Impaired endothelial glycocalyx facilitated platelet adhesion to
endothelium [199], whereas, reciprocally, biglycan, a constituent of the
glycocalyx of capillaries, inhibited platelet activation and, finally,
macrophage-mediated plaque inflammation [204]. Altogether, there
exist numerous mechanisms by which glycocalyx injury may contribute
to impairment of NO-dependent function, increased endothelial per-
meability, endothelial stiffness, endothelial inflammation and altera-
tions in haemostasis; these pathological processes may reciprocally
promote glycocalyx injury. Angiopoietin-2 has been recently proposed
as an important mechanism contributing to glycocalyx integrity,
endothelial permeability, endothelial nanomechanics and inflammation
with Tie2 activation as a novel therapeutic target [205,206]. However,
little is known of how these processes are regulated by specific redox-
based mechanisms (some are mentioned in Fig. 2). We can only pre-
sume that non-specific interventions targeted to oxidant stress improve
glycocalyx integrity, and this could contribute to the improvement of
endothelial function.
As summarised in Fig. 2, a number of redox switches and specific
mechanisms are described in the numerous components of the multi-
factorial phenotype of endothelial dysfunction, but the importance of
these mechanisms in the pathophysiology of endothelial dysfunction
and associated diseases is far from understood. For example, the en-
dothelin-1 mRNA promoter is stabilised by ROS, and vice versa: en-
dothelin-1 can stimulate NADPH oxidase activity and expression levels
Table 3
Important clinical trials and meta-analyses on the effects of antioxidant therapy on cardiovascular disease or all-cause mortality. Positive and negative outcomes are
listed.
Positive studies Marker/intervention, outcome Included subjects Reference
Systematic review and meta-analysis on association of lutein plasma levels
with cardiometabolic health (coronary heart disease, stroke,
metabolic syndrome) across the life course
Lutein ↑ indicates lower risk 387,569 participants [380]
Prospective population study (EPIC-Norfolk) on association of plasma
ascorbic acid levels with mortality in men and women
Vitamin C ↑ indicates lower risk 19,496 participants [177]
Meta-analysis on association of xanthine oxidase inhibitor therapy with
cardiovascular events and hypertension in patients
XOi therapy no effect on CV death, lower risk
for major CV events and hypertension
10,684 patients [175]
Meta-analysis on association of combined ACEi and XOi therapy with
event-free survival of post-AMI patients
XOi and ACEi increases event-free survival in
post-AMI patients
3,630 post-AMI patients, 525 treated [381]
Systematic review and meta-analysis on association of polyphenol-rich
interventions with cardiovascular risk factors in haemodialysis
Polyphenols decrease cardiovascular risk
markers
520 participants [382]
A randomised controlled trial and an updated meta-analysis on
association of curcuminoid-piperine combination therapy with
antioxidant and anti-inflammatory effects of in subjects with
metabolic syndrome
Polyphenols increase SOD activity, reduce
MDA and CRP
281 participants [383]
Systematic review and meta-analysis on association of resveratrol
supplementation with endothelial function, blood pressures and other
parameters among patients with metabolic syndrome and related
disorders
Resveratrol increased FMD, no effect on blood
pressure; reduced body weight, triglycerides,
blood glucose
? [222,384]
PREDIMED study on association of Mediterranean diet with
cardiovascular health status – blood pressure, lipid profiles,
lipoprotein particles, inflammation, oxidative stress, carotid
atherosclerosis and expression of proatherogenic genes and
thrombosis
Mediterranean diet improves CV health and
decreases prevalence of metabolic syndrome
7,447 participants, 288 major CVD
events
[385]
Negative studies Marker/intervention, outcome Included subjects Reference
Systematic review and meta-analysis on association of mortality in
randomised trials with antioxidant supplements for primary and
secondary prevention
β-carotene, vitamin E/D ↑ increased risk,
vitamin C, Se no effect
232,606 participants [180]
Randomised controlled trial (HOPE-TOO) on association of long-term
vitamin E supplementation with cardiovascular events or cancer
Vitamin E ↑ increased risk for HF, no effect on
other CV events and cancer
3,994 participants [386]
HOPE study on association of long-term vitamin E supplementation with
cardiovascular outcomes in people with mild-to-moderate renal
insufficiency
Vitamin E ↑ no effect on major CV events and
proteinuria
9,541 participants, 993 renal
insufficiencies
[387]
Meta-analysis of randomised trials on association of supplementation of
antioxidant vitamins for the prevention of cardiovascular disease with
all-cause and CV death
Vitamin E ↑ no effect on CV/CBV and other
death; β-carotene ↑ increased risk of CV and
other death
81,788 (vitamin E) and 138,113 (β-
carotene) patients
[388]
HOPE study on association of long-term vitamin E supplementation with
cardiovascular and all-cause death in people with cardiovascular
disease or diabetes
Vitamin E ↑ no effect on CV and other death,
risk for major CV events
9,541 participants [389]
Clinical studies in progress (on CVD or disease with increased CV
risk)
Number of clinical trials Lead compounds Reference
NRF-2 activators for rheumatoid arthritis and psoriasis, obstructive sleep
apnoea, chronic kidney disease, T2DM, diabetic nephropathy, non-
alcoholic fatty liver disease, pulmonary hypertension, intracerebral
haemorrhage, acute ischaemic stroke
> 90 phase I–IV trials Bardoxolone methyl,
dimethylfumarate, sulforaphane
[218]
NOX inhibitors for T2DM associated with diabetic nephropathy, stroke;
may also be useful for CVD, non-alcoholic fatty liver disease






Abbreviations used are: XOi (=xanthine oxidase inhibitor); HF (=heart failure); CV (=cardiovascular); CBV (=cerebrovascular) ACEi (=angiotensin converting
enzyme inhibitor); AMI (=acute myocardial infarction); SOD (=superoxide dismutase); MDA (=malondialdehyde); CRP (=C-reactive protein); CVD (=cardio-
vascular disease).
A. Daiber and S. Chlopicki Free Radical Biology and Medicine 157 (2020) 15–37
21
[189]. Finally, prostaglandin formation is redox-regulated by the ‘per-
oxide tone’ needed for the activity of cyclooxygenase-1/2 and in-
activation of prostacyclin synthase by tyrosine nitration. As a con-
sequence of these two oxidative processes, a switch of the prostanoid
synthesis to thromboxane A2 inducing a vasoconstrictory and ag-
gregatory phenotype can be observed under oxidative stress conditions
[189].
Altogether, given the complex multiparametric nature of en-
dothelial dysfunction, a multitarget therapeutic strategy should be
adopted, similar to the recent paradigm shift in the cardioprotection
field [207]. Thus, pharmacotherapy of endothelial dysfunction should
be therapeutically targeted simultaneously to multiple pathomechan-
isms of a dysfunctional endothelium as detailed in Fig. 2. Indeed, it is
unlikely that the improvement in function of a single endothelial me-
chanism will be effective in restoring complex multifactorial mechan-
isms of endothelial dysfunction, unless restoring the one chosen com-
ponent of dysfunctional endothelial machinery will improve all the
others [32,122]. Whether this may be achieved by choosing suitable
redox signalling pathways remains to be established.
Surprisingly, drugs with a broader spectrum of pharmacological
action on endothelium and vascular walls constitute the forefront of
pharmacology of endothelium [32]. Paradoxically, better under-
standing of the profile of endothelial effects of established cardiovas-
cular drugs effective in the treatment of CVD is mostly achieved after,
not prior to, the drug introduction to clinics, and in some cases was
unexpected. These discoveries of mechanisms of action of established
cardiovascular drugs on endothelium and vascular walls may help to
better design efficient redox-based drugs to improve oxidant stress,
endothelial dysfunction and vascular inflammation.
3. Pharmacology of the endothelium based on established
cardiovascular drugs and experimental/future approaches
3.1. Established cardiovascular drugs
According to a number of reports in the literature, endothelial
dysfunction, atherosclerosis and the late cardiovascular complications
of these phenomena are associated with chronic activation of the local
and/or circulating renin-angiotensin-aldosterone system (RAAS).
Suggesting a role of inappropriate ROS production in this setting, dia-
betic patients show particularly beneficial responses to miner-
alocorticoid receptor blockade [208], ACE inhibitor [209], AT1-re-
ceptor blockade [210] and renin inhibitor [211] therapy. Statin therapy
has also been shown to beneficially affect diabetic cardiovascular
complications [212]. This is because ACE inhibitors and statins have
antioxidant, anti-inflammatory, anti-thrombotic and vasoprotective
properties [32,60] and the effects of ACE inhibitors are also shared to
some extent by other RAAS inhibitors.
These established cardiovascular drugs improve cardiovascular
prognosis by lowering oxidative stress levels, inflammation and med-
iators of vascular dysregulation such as lipids and vasoconstrictors
(reviewed in Refs. [60,213–215]). An in-depth review of the effects of
Fig. 2. Endothelial dysfunction – a complex multifactorial phenotype. Processes contributing to endothelial (vascular) dysfunction are not limited to the
impaired NO-dependent function but involve also dysregulation of numerous other vasoactive mediators: glycocalyx disruption, endothelial (vascular) stiffness,
increased endothelial permeability, endothelial inflammation, and alterations in thrombotic or fibrinolytic mechanisms. Known redox switches in these components
are shown above these processes and are listed in detail in Table 4. Modified from Ref. [329].
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established cardiovascular drugs on specific oxidative stress markers in
patients with preestablished CVD has been previously published [174].
Surprisingly, these two classes of drugs – ACE inhibitors and statins
introduced to clinical medicine to lower arterial blood pressure or
blood cholesterol levels, respectively, targeted to inhibit ACE in the
blood or HMG-CoA reductase in the liver – exert comprehensive vaso-
protective actions, based partially on their primary modes of action but
also on complementary endothelial mechanisms, such as improvement
of NO/cGMP signalling by beneficial modulation of the redox switches
described in Fig. 2 [32]. A mechanistic proof of the antioxidant effects
of RAAS inhibitors on NO/cGMP signalling is based on the observation
that in patients treated with ramipril or losartan, vitamin C did not
improve NO-dependent function [216], in contrast to the seminal study
in which the degree of vitamin C–dependent improvement of en-
dothelial function (FMD) was interpreted as the vascular oxidative
stress burden with implications for cardiovascular prognosis of CAD
patients [89]. The beneficial vasoprotective effects of statins may be
also related to the induction of the Nrf2–heme oxygenase-1 system as
well as improved function of endothelial progenitor cells [217], and
cardiovascular protection by Nrf2 activators has been evaluated in over
90 clinical trials for cardiovascular and other indications (for an over-
view see Ref. [218]).
The ETA/B-receptor blockade confers improved prognosis in patients
with pulmonary hypertension [219], which may be explained at least in
part by decreased oxidative stress and inflammation, as reported by
animal studies [220,221]. Multiple beneficial studies have also been
published on the cardioprotective effects of resveratrol, as a prototype
nutraceutical drug [222–224]. A summary of important clinical trials
supporting antioxidant effects of established cardiovascular drugs in
patients with preestablished CVD is also presented in Table 3.
A number of candidates of other drug classes also display highly
beneficial vasoprotective effects. Examples include the third-generation
β1-selective β-blocker nebivolol that stimulated endothelial NO for-
mation [225–227], thereby reversing endothelial dysfunction in pa-
tients with essential hypertension [228], improved oxidative stress in a
rat model of hypertension [229] and prevented multiple complications
in experimental MI [230]. Furthermore, the third-generation β-blockers
nebivolol and carvedilol display antithrombotic effects not related to
their β-blocking activities [231]. Hydralazine was one of the first an-
tihypertensive drugs in clinical use, now mainly used for treatment of
Table 4
Adverse redox switches and redox regulated systems involved in the control of vascular tone (as shown in Fig. 2).
Targets and mechanism of redox regulatory pathways Reference
ROS cause activation of the sympathetic nervous system with release of vasoconstrictors (e.g. catecholamines) in the phenol renal injury and Goldblatt
(2K–1C) models of hypertension.
[392–394]
ROS cause activation of the renin-angiotensin-aldosterone system (RAAS) and vice versa in AT-II or aldosterone-driven cardiovascular remodelling and
hypertension.
[395–398]
Oxidative breakdown of nitric oxide by superoxide radical anions is well-established and contributes to control of vascular tone as shown by beneficial
vasodilatory effects of superoxide dismutase.
[146,399,400]
Oxidative depletion of the eNOS cofactor tetrahydrobiopterin causes uncoupling dysfunction of eNOS with diminished nitric oxide formation. In
concert with other redox switches in eNOS (e.g. oxidative disruption of the zinc-sulphur-centre, S-glutathionylation, ADMA synthesis/degradation
and adverse redox-driven phosphorylation by PKC and PYK-2), this provides a substantial redox-regulatory network in the vasculature with
relevance for hypertension and diabetes.
[145,297,331,401–404]
Oxidative inhibition of prostacyclin synthase by nitration of tyrosine 430, peroxide-driven activation of cyclooxygenase-1/2 and oxidative inhibition of
cyclooxygenase-2 by tyrosine nitration provide redox control of prostanoid synthesis and vascular tone with relevance for diabetes, atherosclerosis,
diabetes, nitrate tolerance and sepsis.
[14,405–412]
Redox regulation of soluble guanylyl cyclase by thiol oxidation and S-nitros(yl)ation modulates the NO/cGMP signalling cascade. Downstream
oxidative activation and upregulation of phosphodiesterases further contribute to this redox-regulatory network.
[14,187,413–417]
The promoter of the potent vasoconstrictor endothelin-1 under oxidative stress conditions leads to its upregulation. Vice versa, endothelin-1 stimulates
NADPH oxidase-driven ROS formation, representing another vicious redox circle with relevance for cardiovascular disease.
[220,418–420]
HMGB1 is a central regulator of inflammation and forms complexes with central mediators of inflammation (e.g., TLR4, CXCL12 and RAGE), with
subsequent recruitment of inflammatory cells and production of cytokines. It thereby represents a major damage-associated molecular pattern
(DAMP). HMGB1 is also a central redox hub in the inflammatory cascade via redox modification of several critical cysteine residues. HMGB1 has
important implications for vascular inflammation.
[50,421–423]
Activation of the NLRP3 inflammasome, another central regulator of the inflammatory cascade, controls the innate immune defence and the production
of essential pro-inflammatory cytokines (e.g. IL-1β). It can be activated by ROS (e.g. from mitochondria or NADPH oxidase) by complex formation
with thioredoxin-interacting protein (TXNIP) on disulphide bridge formation within NLRP3, interaction with thioredoxin/NFkB, activation of
NRF2 or free mtDNA.
[50,90–92,424–426]
Direct redox regulation of central transcription factors such as NFkB, HIF-1α, PTEN, STAT3, S100A9, NEMO and p53 are well established and
formation/release of damage-associated molecular pattern (DAMPs) such as oxidised DNA or free mtDNA under oxidative stress conditions
represent other concepts of redox control of vascular inflammation.
[50,421,427,428]
The glycocalyx forms a network of proteoglycans (e.g. syndecan) and modified sugars (e.g. glycosaminoglycans) covering the endothelial surface with
important functions for microvascular homeostasis. It is redox-regulated by oxidative degradation of glycosaminoglycans to chloramides by
hypochlorous acid. Other free radicals such as hydroxyl and carbonate anion radicals also contribute to the oxidative degradation of the
glycocalyx. The shed glycocalyx fragments have potent immunogenic potential.
[429–431]
Thrombosis is redox-regulated by various mechanisms. Mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 5 (ERK5),
represents a redox sensor that promotes thrombosis by an oxidised low-density lipoprotein (oxLDL), tyrosine kinase (cSrc), NADPH oxidase and
ROS-dependent mechanism under hyperlipidaemic conditions.
[432]
Tissue factor activation increases the risk for thrombosis and is redox-activated via disulphide bridge formation in a thioredoxin-dependent manner.
The antioxidant enzyme paraoxonase-2 contributes to the control of endothelial tissue factor activity and oxidative stress generally increases the
expression of tissue factor.
[433–437]
Nitrated fibrinogen and plasminogen represent thrombotic risk markers. Nitrated plasminogen is less efficiently converted to plasmin, which is
important for resolution of thrombus. Vice versa, plasminogen activator inhibitor-1 (PAI-1) is inhibited by oxidation in a NADPH oxidase-
dependent manner. PAI-1 expression is regulated via NOX-4-derived ROS and p38 MAPK activation.
[438–443]
Thrombin triggers ROS formation via GPIbα, protease-activated receptor (PAR)-4 and NOX-1 signalling axis. Likewise, activated factor X (FXa) via
NOX-1 confers redox regulation of PAR-2.
[444,445]
Vascular cell proliferation can be controlled by cysteine/cystine ratio affecting the activity and level of transforming growth factor (TGF)-β1. Likewise,
NOX-4 activation controls TGF-β1 dependent differentiation of cardiac fibroblasts.
[446,447]
Fibrogenesis is controlled by redox-regulated microRNAs (redoximiRs). [448]
Oxidative stress conditions facilitate the trans-differentiation of smooth muscle cells to osteoblasts and thereby the process of vascular calcification.
Likewise, oxidised low-density lipoprotein (oxLDL) triggers calcification via Runx2/bone morphogenetic protein (BMP)/Wnt signalling involving
NADPH oxidase–derived ROS.
[195,449,450]
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pre-eclampsia [232]. It experienced a revival when a dramatic im-
provement of heart failure mortality was reported with combination
therapy of hydralazine and isosorbide dinitrate (A-HeFT) [233,234],
potentially related to its strong antioxidant effects by peroxynitrite
scavenging that prevent organic nitrate–induced oxidative stress and
nitrate tolerance [235,236]. Pentaerithrityl tetranitrate (PETN) is the
only organic nitrate in clinical use devoid of side effects such as oxi-
dative stress, nitrate tolerance and endothelial dysfunction [190,237].
The molecular explanation for the beneficial effects of PETN, not shared
by other nitrates, is the induction of heme oxygenase-1 [238,239] and
hundreds of other genes in an Nrf2-dependent fashion [240]. The
pleiotropic effects of these three drugs and others have been discussed
in detail previously [60].
Current evidence suggests that SGLT-2 inhibitors (e.g. empagli-
flozin) are more effective than both GLP-1 agonists (e.g. liraglutide) and
DPP-4 inhibitors (gliptins) in reducing the risk of hospitalisation for
heart failure (HHF) in T2DM (87,162 participants) [241], although the
latter showed more potency in reducing HHF in T2DM than sulpho-
nylureas (e.g. glibenclamide) and thiazolidinediones (glitazones;
127,555 patients in the meta-analysis) [242]. Both drug classes have
cardioprotective effects in models of MI [243–246] and have potent
anti-inflammatory properties in humans [247–249] and animal models
of atherosclerosis [250–253], as well as antioxidant and antithrombotic
effects in animal models of sepsis for GLP-1/DPP-4-based drugs
[254–256] and of T1DM/T2DM for empagliflozin [257,258].
Surprisingly, the benefits of dapagliflozin in heart failure have been
recently shown to have a similar extent in patients with and without
diabetes [259], indicating the novel mechanism of action of SGLT-2
inhibition, including endothelium-targeted mechanisms that were not
considered seriously before. In fact, SGLT2 inhibition (canagliflozin/
dapagliflozin/empagliflozin) prevented hyperglycaemia-induced en-
dothelial dysfunction and oxidant stress [260], which could involve the
activation of AMPK or other mechanisms [261–264]. Furthermore,
SGLT2 inhibition preserved and restored the structural integrity of the
glycocalyx, which could explain the anti-inflammatory effects of these
compounds in the presence of a pro-inflammatory environment [265].
3.2. Targeting eNOS dysfunction and uncoupling by drugs improving
vascular redox state and NO (downstream) signalling
Based on the described appreciable redox regulation of the eNOS/
NO/sGC/cGMP axis in various CVD, this signalling pathway represents
an attractive target for pharmacological therapy [14]. Several of the
therapeutic agents that target this signalling pathway represent real
success stories, as demonstrated by the following examples. The NO
replacement therapy by organic nitrates is a mainstay in cardiovascular
therapy of stable angina, congestive heart failure and acute coronary
syndromes, despite limitations due to the development of nitrate tol-
erance and endothelial dysfunction under chronic therapy that are
mainly related to the induction of oxidative stress by most organic ni-
trates [190]. Phosphodiesterase inhibitors prevent the enzymatic de-
gradation of cGMP (and cAMP); prominent examples are sildenafil and
cilostazol. They are used for multiple indications comprising erectile
dysfunction, pulmonary hypertension and a number of cardiac diseases,
and have been reported to prevent endothelial dysfunction, oxidative
stress and inflammation (reviewed in Ref. [266]). The fact that cGMP-
degrading phosphodiesterases are also activated or upregulated by ROS
further increases their benefits under oxidative stress conditions
[190,191]. Activators and stimulators of the sGC represent a novel class
of repair drugs of an oxidatively damaged sGC enzyme; prominent ex-
amples are Cinaciguat™ (BAY 58–2667) and Riociguat™ (BAY
63–2521), which are approved for clinical use in the treatment of dif-
ferent forms of pulmonary hypertension and heart failure [267,268].
They are intended to be used for the therapy of pulmonary hypertension
and heart failure but also for other indications such as arterial hy-
pertension, renal fibrosis or failure, liver cirrhosis, erectile dysfunction,
atherosclerosis, restenosis, thrombosis and inflammation (reviewed in
Ref. [269]). Additionally, direct targeting of eNOS expression and
function by so-called eNOS enhancers (e.g. AVE9488 [270] and
AVE3085 [271]) and tetrahydrobiopterin replacement therapy (e.g. by
folate [272] or sepiapterin [273]) may represent potential therapeutic
strategies in the future, as soon as the drugs themselves as well as their
administration are optimised (for review see [186]). However, it must
be taken into account that a number of interventions are improving NO-
dependent endothelial function without strong anti-atherosclerotic ef-
fects [118,274–276]. On the other hand, inhibition of multiple me-
chanisms of endothelial dysfunction by statins or ACE inhibitors results
in pronounced anti-atherosclerotic effects, which may be more im-
portant for the long-term prognosis of patients [32, 49] (see Section
3.1).
3.3. Actual and future strategies for thiol-targeting redox drugs for
cardiovascular therapy
The classical thiol-targeting therapeutic approach is based on ad-
ministration of reduced thiol drugs such as N-acetylcysteine or α-lipoic
acid, leading to higher levels of reduced GSH and cysteine in serum or
plasma and tissues, reduced oxidative stress, and improved functional
parameters in various disease settings or pharmacological complica-
tions (see Table 5). Both thiols have beneficial cardiovascular effects
[176,277]. Besides the direct antioxidant effect by scavenging ROS and
RNS, these thiols may also interact with proteins and enhance enzy-
matic activity by redox regulation – in principle, any enzyme with a
sulfhydryl group involved in its activity can be targeted by N-acet-
ylcysteine or α-lipoic acid.
In particular, the dithiol α-lipoic acid can easily reverse enzymatic
inactivation by S-glutathionylation, sulfenic acid or disulphide bridge
formation. This has been demonstrated for the cytoprotective enzyme
mitochondrial aldehyde dehydrogenase (ALDH-2), which has two to
three cysteines in the active site pocket (depending on the species), and
one of these thiol groups is essentially involved in the enzymatic ac-
tivity [278]. Whereas ALDH-2 confers cytoprotection and prevents
cardiac dysfunction [279], representing the major bioactivating
pathway for nitroglycerin-dependent vasodilation [280,281], this en-
zyme is also highly redox-regulated and easily oxidised by peroxyni-
trite, electrophiles or nitroglycerin-derived ROS/RNS [282–284]. Since
oxidation and inactivation of ALDH-2 cause accumulation of toxic al-
dehydes such as 4-hydroxynonenal [285], this may lead to cardiac
dysfunction [286]. Of note, α-lipoic acid is a potent activator of ALDH-2
and thereby improves nitroglycerin vasodilatory and anti-ischaemic
effects in rat models [283,287] and humans [288]. In addition, α-lipoic
acid improves diabetic polyneuropathy [176] by decreasing AGE levels
and downstream RAGE signalling [289], and ameliorates endothelial
function in patients with diabetes [290].
N-acetylcysteine was used in the past to preserve the vasodilator
and antiaggregatory potency of antianginal drugs such as nitroglycerin
and isosorbide dinitrate (Table 5 and reviewed in Ref. [291]). Most
likely, these beneficial effects are also based on preservation of ALDH-2
activity, suppression of organic nitrate induced oxidative stress or di-
rect activation (or repair) mechanisms of eNOS or sGC, which are both
prone to oxidative uncoupling and inactivation. Besides decreasing
oxidative stress and preserving vascular function in a number of animal
models of oxidative stress, it may show benefits on cardiac surgery
complications and reduce DNA damage in children with β-thalassaemia
(Table 5).
Novel strategies for thiol-based drugs may be based on H2S-re-
leasing drugs, which may form a complex redox-regulatory network
with potent vasodilator properties [292,293]. The enzymatic targets of
H2S have been reviewed in detail, comprising angiogenesis, vasor-
elaxation, atheroprotection and permeability (Fig. 3) [294], which may
show the future direction for development of more site-specific drugs.
Multiple targets for H2S-releasing drugs have been identified and
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summarised for pre- and postconditioning and remote conditioning in
MI, reperfusion injury and cardioprotection, such as mitochondrial
permeability and activation (mPTP, KATP, PKC), eNOS/cGMP signal-
ling, the ERK/GSK3β pathway and JAK2/STAT-3/iNOS signalling
[295]. The interest in H2S-releasing drugs for therapeutic exploitation is
also reflected by the large number of patents filed for this drug class
[296].
S-glutathionylation at cysteine residues Cys689 and Cys908 re-
presents an important redox switch in eNOS leading to uncoupling of
the electron flow within the enzyme and superoxide formation
[297,298]. This redox-regulatory mechanism gained even more biolo-
gical relevance with results indicating that eNOS S-glutathionylation
can be biologically reversed by glutaredoxin-1 (Grx-1) [299]. In gen-
eral, glutaredoxins confer important redox signalling (pro- or anti-
oxidant depending on the cell type and disease conditions) [300] and
may be implicated in antiatherosclerotic protection of the cardiovas-
cular system [301]. GSH and Grx1 provide an alternative mechanism to
thioredoxin and thioredoxin reductase for peroxiredoxin-2 (Prx2) re-
cycling, and Prx2 represents a major defence mechanism against hy-
drogen peroxide–mediated oxidative stress [302]. Grx-1 deficiency
causes fatty liver and dyslipidaemia by S-glutathionylation and in-
hibition of sirtuin-1 (Sirt-1), suggesting that upregulation of hepatic
Grx-1 may be a beneficial strategy for NAFLD [303]. Grx-2 has also
been shown to play an essential role in the development of the vascular
system by preventing S-glutathionylation of sirtuin-1 and thereby pre-
serving the activity of this NAD+-dependent protein deacetylase and
epigenetic regulator [304], suggesting that specific targeting of the
different isoforms may be important. Grx-2 deficiency causes increased
superoxide and hydrogen peroxide release from cardiac and liver mi-
tochondria [305]. Many more potential targets of pharmacological
modulation of protein S-glutathionylation in CVD and other diseases,
including ryanodine receptors, ion channels and pumps such as SERCA
and various potassium channels, kinases such as Ras/MEKK/c-Jun/Akt/
PKC, apoptosis pathway constituents such as p53/caspase, and central
regulators of inflammation such as NFkB are considered [306,307]. The
S-glutathionylation of the Na+–K+ pump in the cardiovascular system
seems to represent another redox key mechanism that controls cardi-
ovascular health [308]. Thiol-dependent regulatory mechanisms (e.g.
thioredoxin [Trx]/Grx-based) have also been discussed in detail for
redox control of vascular homeostasis [309], protein degradation
[310], ischaemic preconditioning [311] and myocardial remodelling
[312]. Therefore, pharmacological targeting of Trx, Grx, peroxiredoxin
(Prx) and protein disulphide isomerase (PDI) enzymes represents an
attractive redox-based therapeutic approach. Besides the preclinical
Table 5
Important animal experimental studies, clinical trials and meta-analyses on the effects of thiol-based antioxidant therapy on cardiovascular disease or all-cause
mortality.
Animal (cell culture) experimental studies Marker/intervention, outcome Included studies Reference
Systematic review on the protective effect of N-acetyl cysteine against diabetes-
associated cardiovascular complications in animals and cultured cells
NAC improves diabetes-associated
complications (ROS, MI)
49 independent animal and
cell culture studies
[451]
Animal study on N-acetylcysteine, vitamins and other natural antioxidants
prevention of CBrCl3-induced oxidative tissue damage in vivo in a rat model
NAC in combination with lipophilic
antioxidants confers best protection
– [452]
Animal study on N-acetylcysteine prevention of vascular dysfunction and
endothelial epigenetic programming in intrauterine growth–restricted guinea
pigs
NAC prevents complications in intrauterine
growth restriction
– [453]
Study on effects of N-acetylcysteine in combination with nitroglycerin on
aggregation of isolated platelets
NAC/GTN improves IC50 for aggregation 50-
fold over single drugs
– [454]
Animal study on effects of reduced lipoic acid on redox regulation of
mitochondrial aldehyde dehydrogenase (ALDH-2) activity and nitroglycerin
tolerance
α-lipoic acid confers activation of
cytoprotective ALDH-2 and prevents nitrate
tolerance
– [283]
Clinical trials and meta-analyses Marker/intervention, outcome Included subjects Reference
Meta-analysis (ALADIN I, ALADIN III, SYDNEY, NATHAN II) on association of
alpha-lipoic acid supplementation with symptomatic polyneuropathy in
diabetic patients
α-lipoic acid therapy improves polyneuropathy 1,258 patients [176]
Systematic review and meta-analysis on association of antioxidant
supplementations with atrial fibrillation after cardiac surgery
NAC (and vitamin C or PUFA) improves atrial
fibrillation
4,278 patients with cardiac
surgery
[455]
Systematic review and meta-analysis on effects of high/low-dose N-acetylcysteine
on chronic obstructive pulmonary disease
NAC at high dose decreased COPD-associated
complications
11 studies [456]
Meta-analysis on association of N-acetylcysteine with prognosis of sepsis and
systemic inflammatory response in adults
NAC had no effect on outcome 2,768 patients [457]
Clinical trial on effects of alpha-lipoic acid and ascorbic acid on endothelium-
dependent, nitric oxide–mediated vasodilation in diabetic patients
α-lipoic acid therapy improves endothelial
function in diabetes
11 Ctr, 39 patients [290]
Randomised clinical trial on N-acetylcysteine reduction of oxidative stress and
DNA damage in children with β-thalassaemia
NAC reduced oxidative stress index and DNA
damage (comet assay)
28 Ctr, 75 patients [458]
Clinical trial on N-acetylcysteine improvement of coronary and peripheral
vascular function in patients undergoing cardiac catheterisation
NAC potentiates ACh-mediated coronary
vasodilation
16 patients [459]
Clinical trial on effects of N-acetylcysteine in combination with nitroglycerin and
streptokinase on evolving acute myocardial infarction in patients undergoing
cardiac catheterisation
NAC decreases MDA and increases GSH;
improves perfusion and left ventricular
function by trend
27 patients [460]
Double-blind, randomised, crossover study on N-acetylcysteine prevention of
isosorbide dinitrate induced nitrate tolerance and loss of anti-ischaemic
potency in patients with angina pectoris or heart failure
NAC prevents ISDN-induced ROS-associated
nitrate tolerance
10 patients; 14 patients [461,462]
Clinical trial on effects of N-acetylcysteine on nitroglycerin-induced nitrate
tolerance, loss of venodilation and potentiation of vasodilation in patients
with coronary artery disease or angina pectoris
NAC prevents GTN-induced ROS-associated
nitrate tolerance
20 patients; 10 patients; 16
patients; 18 patients
[463–466]
Double-blind, randomised clinical trial on effects of N-acetylcysteine in
combination with nitroglycerin on acute myocardial infarction and blood
pressure in patients with severe unstable angina pectoris
NAC/GTN confers best protection against AMI
but causes hypotension
46 patients [467]
Abbreviations used are: NAC (=N-acetyl cysteine); MI (=myocardial infarction); PUFAs (=polyunsaturated fatty acids); COPD (=chronic obstructive pulmonary
disease); ACh (=acetylcholine); MDA (=malondialdehyde); GSH (=glutathione); ISDN (=isosorbide dinitrate); GTN (=nitroglycerin); AMI (=acute myocardial
infarction).
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evidence presented here, it is also encouraged by the fact that thiol
oxidation represents a cellular response to oxidative stress [313], while
thiol reduction and disulphide bond exchange by PDI are involved in
integrin receptor activation [314].
However, it remains to be established whether eNOS S-glutathio-
nylation represents a drug-targetable pathomechanism, since, para-
doxically, research has found Grx-1 knockout mice were protected from
AT-II induced vascular oxidative stress and dysfunction, potentially
related to impaired NADPH oxidase activation by beneficial S-glu-
tathionylation signalling [315]. Since the NADPH oxidase activation
process relies on a complex thiol–disulphide mechanism, catalysed by
PDI [316], overexpression or pharmacological activation of Grx-1 may
be detrimental under certain conditions. Additional concerns for
pharmacological activation of Grx-1 are based on the observation that
glutathione adducts induced by ischaemia and deletion of Grx-1 stabi-
lise HIF-1α and improve limb revascularisation [317]. Whether the
antiangiogenic effect of Grx-1 activation or overexpression may be
pharmacologically exploited for anti-tumour therapy remains to be
established. Finally, upregulation of Grx-1 activates microglia and
promotes neurodegeneration, all of which contribute to the progression
of Parkinson's disease [318].
Thioredoxin (Trx), glutaredoxin (Grx) and peroxiredoxin (Prx) have
been implicated in a large number of CVD, including ischaemic heart
disease, cardiac hypertrophy, diabetes, obesity, atherosclerosis and
hypertension (reviewed in Ref. [319]). Accordingly, these enzymes
were proposed as biomarkers as well as for gene therapy in CVD
[307,319,320]. The half-life for recombinant human Trx-1 in the
plasma of rodents or monkeys is one to 8 h but can be prolonged by
polyethyleneglycol modification [321]. Most data are available for Trx-
1 gene delivery in CVD therapy, which has been broadly studied at the
preclinical level, but beneficial effects of gene delivery or tissue-specific
overexpression of Trx-2, Grx-1, Grx-2, Prx-3 and Trx reductase have
also been reported in different CVD models (reviewed in Ref. [319]).
Grx protein expression is most likely regulated via antioxidant response
element (ARE) or electrophile response element (EpRE) in the encoding
gene, explaining induction of Grx by electrophilic or pro-oxidant
compounds: oxidants in general (e.g. H2O2), UVB radiation and che-
mical ROS generators such as adriamycin [306], the radical scavenger
Fig. 3. Thiol-based drugs and future redox therapeutic strategies. Beneficial clinical and preclinical effects of N-acetylcysteine and α-lipoic acid (upper panel).
Beneficial preclinical effects of H2S-releasing drugs (middle panel). Beneficial preclinical effects of glutaredoxin enzymes (lower panel). Contains images from Servier
Medical Art by Servier, licensed under a Creative Commons Attribution 3.0 Unported License.
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tert-butylated hydroxyanisole (BHA) [322], epidermal growth factor,
TGFβ, cyclic AMP, and retinoic acid [323] or 17β-estradiol [323].
Whether these Grx inducers can be exploited therapeutically for re-
versal of S-glutathionylation in specific CVD remains to be established.
Finally, protein disulphide isomerases represent protein-folding cha-
perones and central regulators of cellular functions, and their phar-
macological targeting may represent another thiol-based strategy for
the treatment of cancer and neurodegenerative diseases (reviewed in
Ref. [324,325]).
3.4. Actual and future strategies for ROS scavengers and source-targeting
redox drugs for cardiovascular therapy
Direct ROS scavengers are mainly based on natural compounds such
as vitamins C, E and D as well as thiol-based drugs. Metal complexes
have also been tested in recent years as SOD mimetics, with some
specific developments made, such as ebselen as a GPx mimetic, NXY-
059 and some other spin traps (for review see Ref. [165]). However, so
far none of these drugs are used for broad clinical applications, and only
some are used for niche therapies (e.g. anticancer chemo- or radiation
therapy). Some more recent candidates that are at least in clinical phase
II or III trials are mitochondria-targeted antioxidants such as the direct
ROS scavenger mitoQ [165,326,327] and NRF-2 activators with the
lead compounds bardoxolone methyl, dimethylfumarate and sulfor-
aphane [218]. Strong evidence for the protective NRF-2 concept is also
based on a systematic review and meta-analysis of the antioxidant (by
MDA) and anti-inflammatory (by TNF-α) effects of resveratrol on
multiple organ injury induced by sepsis in animal models (11 combined
studies) [328], since resveratrol is known to act, besides sirtuin-1 sig-
nalling, by activation of the Nrf2-heme oxygenase-1 axis [218]. The
most promising candidates of the group of ROS source inhibitors are
NADPH oxidase inhibitors with the lead compounds GKT136901/
137831 (Genkyotex) and VAS2870/3947 (Vasopharm) [327] and xan-
thine oxidase inhibitors such as allopurinol and febuxostat [327]
(Table 3). Other ROS source inhibitors are monoamine oxidase in-
hibitors (most advanced clinical proof-of-concept trials for depression
and neurodegenerative disease), NOS inhibitors (most advanced clinical
proof-of-concept trials for traumatic brain injury, whereas those for
septic shock failed) and inhibitors of the ROS toxifier myeloperoxidase
(several drug candidates are currently in development; for review see
Ref. [327]).
3.5. Future strategies for redox drugs for cardiovascular therapy – A
personal perspective
Although impairment of •NO-dependent endothelial function re-
presents a central diagnostic approach to measure endothelial dys-
function and has prognostic value, therapeutic strategies targeted to
restore the function of endothelial •NO have failed. •NO donors, L-ar-
ginine and BH4-based approaches do not seem to afford long-term
cardiovascular benefits for CVD, but as known for organic nitrates,
sodium nitroprusside and other •NO donors can be used for acute
management of hypertensive crisis or acute treatment of angina
symptoms. Only strategies targeted to downstream mechanisms of •NO
signalling, including sGC activators and stimulators, or phosphodies-
terase inhibitors, are promising. Thus, attempts to achieve antioxidant
effects by •NO replacement therapy have not endured over time, and
endogenous •NO activation by eNOS enhancers, L-arginine and BH4 has
led to controversial reports or become deadlocked at the drug devel-
opment stage. Furthermore, only •NO donors that have an intrinsic
antioxidant potential such as PETN, inducing HO-1, do not induce
oxidant stress on their own and have proven beneficial in many clinical
indications. Many of the specifically targeted redox-based strategies
have so far not met their expectations, such as NOX inhibitors. On the
other hand, non-specific approaches with H2S donors or N-acet-
ylcysteine have demonstrated vast potential as they target many
mechanisms and most likely many targets. Similarly, some of the es-
tablished cardiovascular drugs are effective in improvement of en-
dothelial function and restoring multiple detrimental and pathophy-
siology-relevant mechanisms, including oxidative stress, vascular
inflammation and prothrombotic mechanisms. Collectively, the data
support that drugs displaying a broader spectrum of pharmacological
action on the endothelium or following a multitarget strategy represent
the best therapeutic approach to treat endothelial dysfunction and ac-
cordingly CVD. This conclusion seems not surprising, given the complex
multifactorial nature of the diseased endothelium with many pathways
and various pathophysiologically relevant functional changes that by
far exceed the loss of homeostatic •NO/O2•‾ balance, although the latter
plays a central but not unique role in the pathophysiology of en-
dothelial dysfunction. Thus, our future therapeutic strategies should be
not limited to restoring •NO/O2•‾ balance but to restoring the whole
complexity of the phenotype of endothelial function maintaining car-
diovascular homeostasis.
Thus, the current challenge is to better understand the relative
importance of various mechanisms of endothelial dysfunction, apart
from •NO/O2•‾ balance, as well as their reciprocal interactions in var-
ious diseases linked to endothelial dysfunction, to propose the most
effective therapeutic approaches. So far, unsurprisingly considering the
multifactorial nature of endothelial dysfunction and CVD, the most
effective vasoprotective redox drugs are rather unspecific thiol-based
antioxidants (Table 5). Improvement of redox balance is also shared by
established cardiovascular drugs. However, their comprehensive me-
chanisms of action on the endothelium and vascular walls were dis-
covered mostly after, not prior to, their introduction to clinical practice,
as was the case with RAAS inhibitors, statins, SGLT-2 inhibitors and
third-generation β-blockers, for example. Against expectation, estab-
lished cardiovascular drugs seem to be still at the forefront of the
pharmacology of endothelial dysfunction, and we can still learn from
their clinical successes how to design novel endothelial-targeted treat-
ments.
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